12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Company News  |  Deals

Ichor Medical, Scancell deal

Ichor extended to July 2016 from July 2014 Scancell's option to commercialize Ichor's TriGrid electroporation system with Scancell's SCIB1. In exchange, Scancell will waive the two-year lock period following the exercise of the first tranche of share options granted to Ichor under a 2009 deal. SCIB1 is a cancer vaccine comprising the melanoma antigen tyrosinase-related protein 2 ( TRP-2; TYRP2; ...

Read the full 327 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >